Search
Hepalink: Phase I Clinical Trial of H1710 Injection Commences with First Subject Dosed
2025-07-18 /
Read about 0 minute
Author：小编
Hepalink has successfully enrolled and dosed the first subject in the Phase I clinical trial of its independently developed innovative drug, H1710 for injection. H1710, a heparin derivative with minimal anticoagulant activity, serves as a potent and selective heparanase inhibitor tailored to treat advanced solid tumors. This Phase Ia clinical trial, an open-label, dose-escalation study, will span three research centers and is anticipated to enroll 36 patients. Currently, no drugs with a similar mechanism are available on the global market.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
